We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
Cap. Flow
+$1.08B
Cap. Flow %
13.6%
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$440M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$270M
3
AFIB
Acutus Medical Inc
AFIB
+$166M
4
ACET icon
Adicet Bio
ACET
+$95.1M
5
TBPH icon
Theravance Biopharma
TBPH
+$68.6M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$119M
2
CI icon
Cigna
CI
+$82.5M
3
NTRA icon
Natera
NTRA
+$64.2M
4
ALEC icon
Alector
ALEC
+$52.6M
5
GKOS icon
Glaukos
GKOS
+$46.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 0.63%
3 Technology 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRLD icon
1
Prelude Therapeutics
PRLD
$370M
$470M 5.91%
+15,594,877
New +$440M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$353M 4.44%
7,406,307
– –
PMVP icon
3
PMV Pharmaceuticals
PMVP
$58.7M
$260M 3.27%
+7,330,423
New +$270M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$250M 3.14%
2,184,500
+28,500
+1% +$3.07M
TPTX
5
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$240M 3.01%
2,745,327
– –
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$234M 2.94%
3,008,755
+140,845
+5% +$9.69M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$2.1B
$219M 2.75%
6,645,100
– –
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$219M 2.75%
1,317,000
-7,100
-0.5% -$972K
MRK icon
9
Merck
MRK
$326B
$215M 2.7%
2,713,377
– –
BMY icon
10
Bristol-Myers Squibb
BMY
$130B
$214M 2.69%
3,549,100
+666,900
+23% +$40.1M
BIIB icon
11
Biogen
BIIB
$30.4B
$203M 2.55%
715,900
– –
BSX icon
12
Boston Scientific
BSX
$68.5B
$185M 2.33%
4,847,300
– –
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$124B
$181M 2.28%
666,100
– –
AFIB
14
DELISTED
Acutus Medical Inc
AFIB
$163M 2.05%
+5,477,958
New +$166M
NTRA icon
15
Natera
NTRA
$36.1B
$152M 1.92%
2,110,700
-1,129,814
-35% -$64.2M
PRVL
16
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$141M 1.77%
13,822,463
– –
ARQT icon
17
Arcutis Biotherapeutics
ARQT
$3.55B
$137M 1.72%
4,673,850
– –
NBIX icon
18
Neurocrine Biosciences
NBIX
$18.4B
$125M 1.57%
1,301,715
+115,800
+10% +$13.4M
BNR
19
Burning Rock Biotech
BNR
$96.9M
$119M 1.5%
474,608
+1
+0% +$237
HUM icon
20
Humana
HUM
$46.7B
$116M 1.46%
280,300
– –
ASND icon
21
Ascendis Pharma A/S
ASND
$16.7B
$113M 1.42%
734,500
-828,486
-53% -$119M
RPTX
22
DELISTED
Repare Therapeutics
RPTX
$105M 1.33%
3,426,325
– –
ETNB
23
DELISTED
89bio
ETNB
$95.7M 1.2%
3,729,442
-275,000
-7% -$8.72M
DXCM icon
24
DexCom
DXCM
$28.9B
$93.3M 1.17%
905,600
– –
TBPH icon
25
Theravance Biopharma
TBPH
$875M
$92M 1.16%
6,219,110
+3,664,640
+143% +$68.6M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2020 Portfolio in Review

As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.

  • OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
  • OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
  • OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
  • OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
  • OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
  • OrbiMed opened 28 new positions and closed 20 in Q3 2020.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.